-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 22, Zhiben Medical announced that the human NTRK1/2/3 gene mutation detection kit (reversible terminal termination sequencing method) has been awarded the "Special Review of Innovative Medical Devices" by the Medical Device Technology Evaluation Center of the State Drug Administration
The human NTRK1/2/3 gene mutation detection kit (reversible terminal termination sequencing method) will be used for the detection of NTRK 1, 2, 3 gene fusion mutations in solid tumors
Larotrectinib is a highly selective TRK inhibitor designed for the treatment of tumor patients with NTRK gene fusion.
Note: The original text has been deleted